Clinical trial
Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection
NCT02973802 is registered in ClinicalTrials.gov with Apitope International NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection
- Lead sponsor
- Apitope International NV
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- February 14, 2018
- Enrollment
- 12 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.